Radiofrequency catheter ablation for atrial fibrillation has become an important therapy for AF; however, recurrence rates remain high. We proposed to determine whether aggressive blood pressure (BP) lowering prevents recurrent atrial fibrillation (AF) after catheter ablation in patients with AF and a high symptom burden.
A trial fibrillation (AF) is the most common sustained arrhythmia and is associated with significant morbidity, mortality, and cost. 1 Radiofrequency catheter ablation for AF has become an important therapy for AF; however, recurrence rates remain high.
2-5 AF recurrence after an ablation may be due to technical limitations of ablation such as recovery of conduction in the antral region of the pulmonary veins, or it may be due to the presence of an arrhythmogenic atrial substrate that is not modifiable by ablation alone. 6 Hypertension is the most common worldwide risk factor associated with the development of AF and has been thought to contribute to an arrhythmogenic substrate. [7] [8] [9] We performed a randomized clinical trial in patients with AF and a high symptom burden to determine whether a strategy of aggressive blood pressure (BP) lowering to a target of 120/80 mm Hg would reduce the occurrence of AF after catheter ablation.
METHODS Study Design
This was a randomized, parallel, open-label clinical trial with blinded end-point evaluation. The study was conducted at 13 tertiary care centers in Canada experienced in catheter ablation of AF and was approved by the research ethics committee at each participating site. An independent data and safety monitoring board reviewed the unblinded data and adverse events at 6-month intervals. All subjects enrolled provided informed consent before randomization. The full protocol is available in the online-only Data Supplement.
Participants
Patients were eligible for inclusion if they had a baseline BP >130/80 mm Hg, had symptomatic paroxysmal or persistent AF, were refractory to or intolerant of at least 1 class I or III antiarrhythmic agent, and were scheduled to undergo catheter ablation. Baseline BP was defined as the average of 2 measurements taken 2 minutes apart with a standard sphygmomanometer completed after the patient had been resting for 5 minutes. If the patients were in AF, 4 measurements were performed. Patients with known moderate to severe renal dysfunction (estimated glomerular filtration rate <30 mL·min −1 ·1.73 m −2 with the CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] calculation) 10 or prior intolerance to an angiotensin receptor II antagonist were excluded.
Initially, only patients with persistent AF were included, but after data were reported suggesting benefit of BP lowering in hypertensive patients with paroxysmal AF, the protocol was revised in September 2013 to include this population. 11 
Randomization and Blinding
Eligible patients were randomly allocated in 1:1 proportions to standard or aggressive BP treatment, with stratification performed by center and by presence of a preexisting clinical diagnosis of hypertension. Patients randomized to the standard BP treatment group received open-label therapy to achieve a target BP according to the 2010 Canadian Hypertension Education Program guidelines, as managed by their attending physician. 12 No study-directed changes to their drug regimen were made unless the BP did not meet guideline criteria. Patients in the aggressive BP treatment group were treated to obtain a target systolic BP ≤120 mm Hg; medications to achieve this target BP were supplied by the study site for a duration that varied between 0 and 6 months before ablation and then for a further 3 months after ablation before any prior outcomes were recorded. Although blinding of participants was not possible, bias was minimized by use of an objective end point adjudicated by a blinded event committee. To avoid bias in the ablation procedure, 2 physicians were involved with each patient's care: the electrophysiologist and the unblinded physician. The electrophysiologist was the physician who performed the catheter ablation; these physicians were blinded to treatment assignment and evaluated the patient only for symptoms related to AF.
Each patient in the aggressive BP treatment group was given an Omron HEM-711CAN automatic sphygmomanometer. Titration of medications in the aggressive BP treatment group occurred at 2-week intervals through telephone followup (Table I and Figure I in the online-only Data Supplement). Antiarrhythmic drugs were discontinued 6 weeks after catheter ablation was performed, except for amiodarone, which was discontinued 4 weeks before the ablation procedure and not restarted after ablation. Further details on the BP titration protocol are found in the online-only Data Supplement.
Procedures
All patients underwent a baseline history and physical examination, ECG, laboratory examination, and quality-of-life assessment.
Clinical Perspective
What Is New?
• This study demonstrates no additional benefit to the addition of aggressive blood pressure lowering over a median of 3.5 months over standard blood pressure therapy in patients undergoing catheter ablation for atrial fibrillation to prevent recurrent atrial arrhythmia.
• A signal of benefit in groups whose blood pressures (<140 mm Hg) were lower at the point of entry into the study and those patients who were older (age ≥61 years) was found.
• The duration of blood pressure lowering in this study did not result in a reduction of recurrent atrial fibrillation after catheter ablation in this population.
What Are the Clinical Implications?
• Determining the point in the atrial substrate pathway where upstream therapy would provide benefit in reducing atrial arrhythmia, reverse the atrial substrate, and lead to improved cardiovascular outcomes could result in significant benefits to the increasing population of patients with atrial fibrillation worldwide.
Randomization to assigned treatment groups occurred between 0 and 6 months before the planned catheter ablation for AF ( Figure II in the online-only Data Supplement). All patients were followed up quarterly for the first year and then at 6-month intervals for a minimum of 12 months and a maximum of 30 months. Quality-of-life assessment and biomarker determination were repeated at 12 months. All patients received a Braemar PER 900 recording device for home transtelephonic monitoring. Patients transmitted routinely twice weekly for 2 weeks every 3 months for the duration of the study until a primary outcome was reached; no further transmissions were obtained once a primary outcome was confirmed by the coordinating center. Use of antiarrhythmic drugs was permitted before randomization and until 6 weeks after ablation but discontinued thereafter, except for amiodarone, which was recommended to be discontinued 3 months before the ablation procedure and not permitted after ablation. β-Blockers (other than sotalol), calcium channel blockers, and digoxin were altered as needed by the local principal investigator. The catheter ablation was performed within 6 months of randomization. The ablation procedure was performed as described below. After access to the right and left femoral veins was obtained, 1 quadripolar electrode was placed in the right ventricle and 1 duodecapolar electrode was placed in the coronary sinus for recording and pacing. Double transseptal catheterization was performed under fluoroscopic guidance. Two long vascular sheaths were introduced into the left atrium. Immediately after the first transseptal puncture, 10 000 U/kg IV heparin was administered through the long sheath. Repeated doses of heparin were given to maintain an activated clotting time of >300 seconds. Three-dimensional maps of the left atrium were constructed with the use of a nonfluoroscopic navigation system (CARTO or ESI). Continuous wide-area circumferential lesions were created encircling right and left pulmonary venous ostia guided by electroanatomic mapping with an irrigated, cooled-tip radiofrequency ablation catheter. Radiofrequency energy could be applied continuously, with change of position every 20 seconds. A maximum temperature of 40°C with maximum power of 40 W was to be delivered, except for the posterior wall, where the power was not to exceed 25 W. Lesions were complete when electrogram amplitude was reduced by ≥80% of baseline. Complete isolation of all 4 pulmonary veins as demonstrated by no pulmonary vein potentials along the antrum or inside of the vein on a circular mapping catheter was targeted to be achieved. If the patient remained in AF, then ablation of complex fractionated electrograms in the coronary sinus and left atria, with or without a roof line, was performed. If AF did not terminate or organize into an atrial tachycardia (AT), consideration was given to a mitral isthmus line followed by ablation of complex fractionated electrograms in the right atrium. If the patient remained in AF, then cardioversion electrically or chemically could be performed.
Repeat ablation was not recommended until after 6 months after the first ablation. Medication compliance was assessed by questioning the patient at each study visit. Patients in the aggressive BP arm were considered compliant if they were taking >80% of the prescribed dose and medications. Adverse events were collected in both treatment groups to document any incidences of hypotension requiring medication adjustment, presyncope, syncope, or emergency department visits or hospitalizations deemed to be due to study procedures.
Periprocedural events from the initial ablation and repeat ablation procedures were documented.
Outcomes
The primary outcome event was time to symptomatic AF, AT, or atrial flutter (AFl) lasting >30 seconds at >3 months after ablation. AF/AT/AFl was defined on telemetry as a mean atrial cycle length ≤400 milliseconds or the absence of organized atrial activity. Symptoms were defined as any one of the following: palpitations, presyncope, fatigue, dyspnea, chest pain, or reduced exercise tolerance.
An events committee blinded to treatment assignment adjudicated all primary outcomes. Secondary outcomes included any recurrent AF/AT/AFl after randomization, any recurrent AF/AT/AFl 3 months after ablation regardless of symptoms, recurrent ablation therapy, thromboembolic events, AF-related emergency department visits, and AF-related hospitalizations.
Statistical Analysis
The recurrence rate for AF/AT/AFl overall in the standard BP treatment group was estimated to be 63% at 1 year. With a 30% relative risk reduction in the first year used as the minimal clinically important difference, a sample size of 184 patients was needed (92 patients in each arm) at a level of significance of 0.05 (2 sided) and 80% power. The minimal clinically important difference was used to determine the recurrence rate in the aggressive arm because there were no trial data on which to base the effect of this therapy. 13 This calculation assumed an exponential survival with all patients followed up to the primary end point or termination of the study and allowed a 1% loss to follow-up in each group and a 0% crossover from each group. This treatment comparison was based on the log-rank test. A dropout rate of 1% from either arm was anticipated.
Descriptive statistics were used to summarize the characteristics of the treatment and control patient groups on demographic and clinical variables. Changes in BP over time were assessed by comparing the mean systolic and diastolic BPs with a repeated-measure mixed model. The primary analysis was on an intention-to-treat basis with a competing-risk model with death as the competing risk. The cumulative incidence function was used to estimate the probability of the outcome in each of the 2 groups, and the subdistribution hazard model proposed by Fine and Gray 14 was used to compare the curves. The intention-to-treat population included all patients who underwent an ablation procedure and were allocated to study therapy, regardless of whether they achieved the BP target. The per-protocol population included all patients in the aggressive BP treatment group who received an ablation, reached target BP of 120/80 mm Hg according to the protocol for BP titration in the aggressive arm, and did not experience a major protocol violation significantly affecting efficacy or loss to follow-up compared with the standard group who received an ablation.
Prespecified subgroup analyses based on a history of hypertension, patient age (greater than or less than the median of the sample), type of AF, duration of AF, CHADS 2 score, left atrial size, sex, BP, body mass index, and sleep apnea were conducted for the primary end point. Potential confounders were assessed, and regression-based models were used to adjust for these effects if needed. Intermittent safety analyses were conducted by the Data Safety and Monitoring Committee, but no interim efficacy analyses were planned. The primary safety analysis included any symptoms of hypotension, adverse events, and serious adverse events. All statistical analyses were performed by the Ottawa Cardiovascular Research Methods Center using SAS version 9. 
RESULTS
From July 1, 2011, through October 4, 2015, a total of 184 patients were enrolled (Figure 1) . Of the 184 patients who underwent randomization, 4 patients exited the study, 1 patient declined ablation, 5 patients were canceled as a result of physician decision about the ablation, and 1 patient underwent ablation for atrioventricular node reentry tachycardia only. A total of 173 patients were assessed for the primary outcome, 88 in the aggressive BP treatment group and 85 in the standard group. The median follow-up was 14.0 months (first and third quartiles, 8.1 and 27.2 months). The clinical characteristics of the patients at baseline were similar between the 2 groups (Table 1) .
At baseline, the mean±SD BP was 142.9±11.0/ 84.9±8.5 mm Hg in the aggressive BP treatment group and 142.2±12.6/84.3±8.5 mm Hg in the standard group (Figure 2) . At 6 months, the BP was lowered to 123.2±13.2/76.7±11.4 mm Hg in the aggressive BP treatment group compared with 135.4±15.7/80.8±10.2 mm Hg in the standard group (P<0.001; Figure 2 and Table II in the online-only Data Supplement). The mean number of antihypertensive medications at baseline was no different between the aggressive BP treatment group and the standard group (1.84±1.14 versus 1.80±0.99). After ablation, the aggressive group participants were on 4.61±1.85 antihypertensive medications compared with 3.00±1.16 in the standard treatment group (P<0.0001). Compliance to antihypertensive medications was >88% at all follow-up visits in the aggressive BP treatment group. No differences in use of rate-controlling drugs after ablation were seen between the aggressive and standard groups (39.3% versus 44.3%, respectively; P=0.50). No difference in use of these medications was observed throughout study follow-up.
The catheter ablation procedure for AF was completed successfully in 88 patients (95.6%) in the aggressive BP treatment group and 85 patients (92.4%) in the standard group. Time from randomization to ablation was a median of 3.5 months (interquartile range, 2.5-4.2 months) in the aggressive treatment group and 3.1 months (interquartile range, 2.6-4.2 months; P=0.578) in the standard group. Acute pulmonary vein isolation was achieved in 93.2% of the aggressive BP treatment group and 94.1% in the standard BP group. Ablation beyond pulmonary vein isolation included ablation of complex fractionated electrograms in 19 of 88 (21.6%) of the aggressive BP group and 20 of 85 (23.5%) in the standard group (P=0.760). No differences in other procedural details were found between the 2 groups. One patient underwent a repeat ablation within the 3-month blanking period (Tables III and IV in the online-only Data  Supplement) .
The primary outcome, recurrent symptomatic AF/AT/ AFl beyond 3 months after ablation, occurred in 106 patients (61.2%). There was no significant difference in the occurrence of the primary outcome between the aggressive BP (54 of 88, 61.4%) and standard BP (52 of 85, 61.2%) treatment groups or the time to first occurrence of atrial arrhythmia (hazard ratio=0.94; 95% confidence interval, 0.65-1.38; P=0.763; Table 2 and Figure 3) . The secondary outcomes did not show any significant differences between the 2 groups except that recurrent AF-related emergency department visits were more frequent in the aggressive BP treatment group (28 [30.4%] In the prespecified subgroups, a significant interaction by the median cutoff age of ≥61 years was found on the primary outcome (hazard ratio=0.58; 95% confidence interval, 0.34-0.97) in favor of the older age group (P for interaction=0.013; Figure 4 ). The effect of each of the treatment arms on BP differed between the age groups ( Figure 5A and 5B). A significant difference in systolic BP at 6 months between the aggressive and standard treatment groups (122.8±14.1 versus 139.0±15.3 mm Hg; P<0.001) was observed in the older group but not in the younger group (123.5±12.6 versus 131.7±15.3 mm Hg; P=0.182).
A second statistical interaction was found. Patients who entered the study with a systolic BP <140 mm Hg were found to have a reduction in recurrent AT/AF/AFl from aggressive BP lowering in contrast to those who had a higher BP at baseline (nominal P=0.022 for interaction).
Adverse events differed significantly between the 2 groups, with hypotension requiring medication adjustment occurring in 26% of patients in the aggressive BP treatment group compared with no patients in the standard BP group. There were more emergency department visits for hypotension in the aggressive BP treatment group compared with the standard group, but this was not statistically significant (2.2% versus 0%). Other reasons for emergency department visit included AF/AFl/ AT (n=26), transient ischemic attack (n=1), hypokalemia ‡Median with interquartile range. There were no significant differences between the 2 groups except for digoxin (P=0.003).
§Sleep apnea that was diagnosed and treated. ‖CHADS 2 score is calculated by congestive heart failure, hypertension, age ≥75 years, diabetes mellitus (each contributing 1 point), prior stroke, or transient ischemic attack (contributing 2 points). 
DISCUSSION
A strategy of aggressive BP treatment for a median duration of 3.5 months before catheter ablation did not reduce the recurrence of atrial arrhythmias after catheter ablation compared with standard BP treatment in a population of patients with paroxysmal or persistent AF with a BP >130/80 mm Hg. With aggressive BP therapy, there was a higher incidence of hypotension requiring medication adjustment. Upstream therapy for AF has been of considerable interest, and benefit has been demonstrated in the primary prevention of AF. A post hoc analysis of the LIFE study (Losartan Intervention for End Point Reduction) found that losartan reduced the incidence of new-onset AF from 10.1 to 6.8 per 1000 patient-years compared with atenolol alone. A meta-analysis examining the effect of angiotensin-converting enzyme inhibition or angiotensin II receptor blockade on the primary prevention of AF in patients with structural heart disease showed similar findings, providing support for the pleotropic effects of these medications. 13, 15 Secondary prevention of AF, however, has not been found to be of benefit with angiotensin-converting enzyme inhibition or angiotensin II receptor blockade. The GISSI-AF study (Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiac Atrial Fibrillation) failed to show any benefit in preventing recurrent AF in a population of individuals with paroxysmal or persistent AF. 16 A single small clinical trial demonstrated a benefit of preventing recurrent AF after cardioversion when pretreatment with irbesartan was A B Figure 2 . Blood pressure in each group.
Red line indicates the standard treatment group; blue line, the aggressive treatment group. Means with 95% confidence intervals (bars) are displayed. A, Total population systolic blood pressure (P<0.001 for difference between groups). B, Total population diastolic blood pressure (P=0.082 for difference between groups). used in addition to antiarrhythmic drugs compared with antiarrhythmic drugs alone. 17 The ACTIVE I trial (Atrial Fibrillation Clopidogrel Trial With Irbesartan to Prevent Vascular Events) failed to show that the pleotropic effects of angiotensin II receptor blockade had any effect on cardiovascular outcomes in patients with AF. 18 Catheter ablation has demonstrated success over current medical therapies for long-term rhythm control, but recurrence remains high, regardless of ablation strategy. 5, 19, 20 A single small randomized clinical trial has examined the effect of BP lowering through renal denervation in patients with uncontrolled hypertension. 11 This study demonstrated a reduction in recurrent AF from 87% to 31% with renal denervation, in addition to pulmonary vein isolation. Other studies have demonstrated the positive effect of weight loss and control of cardiometabolic risk factors on improvement of AF-related quality of life and AF burden. 21 A single-center cohort study has demonstrated reduction of AF in patients who chose to undergo aggressive risk factor modification compared with those who did not before catheter ablation, with an odds ratio of 4.8 (95% confidence interval, 2.04-11.4) predicting arrhythmia-free survival at follow-up. 22 Another single-center randomized trial demonstrated the effect of intense aerobic interval training to reduce recurrent AF in a population of patients with nonpermanent AF who did not undergo catheter ablation. 23 Our study examined an upstream intervention using an angiotensin II blockade-based BP-lowering regimen to reduce the recurrence of atrial arrhythmias after AF ablation is performed to target left atrial substrate remodeling resulting from uncontrolled hypertension. Several ablation strategies, beyond pulmonary vein isolation alone, tested in clinical trials have failed to show any benefit in reducing recurrent AF after ablation. 20, 24, 25 Our study demonstrated a 61.2% recurrence rate at a median of 14 months of follow-up. This high recurrence rate is likely due to the population studied: 76% were hypertensive at baseline and had other comorbidities, including obesity (mean body mass index, 32 kg/m 2 ), sleep apnea (19.6%), and diabetes mellitus (13.6%). Of the 11 prespecified subgroups, 2 nominally significant interactions were observed. First, there was a significant effect on the reduction of atrial arrhythmias after catheter ablation in patients in the older half of the population (age >61 years). In this older age group, a 42% relative risk reduction of recurrent atrial arrhythmias after catheter ablation in the aggressive BP treatment group was observed. The significance of this finding is uncertain in the context of the globally neutral result. However, the larger reduction in BP observed in older patients during the study lends credence to this observation, which should be tested prospectively. Second, we observed a significant interaction between BP on entry to the study and outcome with aggressive BP treatment. This finding may demonstrate that benefit from aggressive BP treatment may need to begin further upstream, before patients reach the threshold of a high AF symptom burden requiring catheter ablation. In this study, patients had failed antiarrhythmic medications and had AF for a median of 30 months and thus were a high-risk group for recurrent AF with an advanced atrial substrate. Both the RACE 3 study (Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure) 26 and the EAST study (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), 27 which examined the effect of catheter ablation early from the onset of AF, recognized that the atrial substrate may become too far advanced to improve outcomes when ablation or another intervention is instituted later in the course of AF.
Our study attempted to improve AF recurrences by targeting an important underlying substrate for AF in those who are highly symptomatic. However, the prognostic importance of the prevention and elimination of AF, in the absence of symptom improvement, remains uncertain. It is apparent that AF is a marker of hypertensive disease, is associated with heart failure, and portends a higher risk of stroke. It is not clear from many clinical trials to date whether the elimination of AF provides any substantial benefit. Both the AFFIRM trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) 28 and AF-CHF trial (Atrial Fibrillation and Congestive Heart Failure) 29 failed to demonstrate a benefit of rhythm control. A post hoc analysis of AFFIRM found that sinus rhythm was associated with an improved prognosis, but this is confounded by the nonrandomized analysis. 30 Both the CABANA study (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) 31 Failure and High Burden Atrial Fibrillation) 32 are attempting to shed some light on this question by examining rate versus rhythm via catheter ablation with cardiovascular end points including death, heart failure hospitalization (RAFT-AF), and stroke (CABANA).
Some limitations to the study that are important to recognize may have contributed to the neutral findings. The patients in the standard treatment arm were well treated, and although we achieved a significant BP difference between the 2 groups, there was overlap between the treatment groups, particularly when both groups had a significant reduction in BP from baseline. This may have resulted in dilution of a positive effect of an aggressive BP treatment regimen. Last, the patients who were included in this study had high-burden AF for a median of almost 30 months; these patients may have had an atrial myopathy that could not be reversed with aggressive BP treatment in combination with ablation.
CONCLUSIONS
This duration of aggressive BP treatment in patients with AF undergoing catheter ablation did not result in a reduction of atrial arrhythmias after ablation. It did result in an increase in adverse events, most notably symptomatic hypotension. Upstream therapy for AF will require further study in randomized clinical trials to better understand its potential benefit in AF prevention.
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